Protalix BioTherapeutics Analyst Ratings
Protalix BioTherapeutics Analyst Ratings
While ratings are subjective and will change, the latest Protalix BioTherapeutics (PLX) rating was a maintained with a price target of $7.00 to $10.00. The current price Protalix BioTherapeutics (PLX) is trading at is $1.45, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/31/2023 | 589.66% | HC Wainwright & Co. | $7 → $10 | Maintains | Buy |
| 05/03/2021 | 382.76% | HC Wainwright & Co. | $11 → $7 | Maintains | Buy |
| 06/08/2020 | 658.62% | HC Wainwright & Co. | $3 → $11 | Maintains | Buy |
| 日期 | 上行/下行 | 分析师公司 | 目标价变化 | 评级变动 | 先前 / 当前评级 |
|---|---|---|---|---|---|
| 10/31/2023 | 589.66% | HC Wainwright & Co. | $7 → $10 | 维持 | 买入 |
| 05/03/2021 | 382.76% | HC Wainwright & Co. | $11 → $7 | 维持 | 买入 |
| 06/08/2020 | 658.62% | HC Wainwright & Co. | $3 → $11 | 维持 | 买入 |
What is the target price for Protalix BioTherapeutics (PLX)?
Protalix BioTherapeutics（PLX）的目标价是多少？
The latest price target for Protalix BioTherapeutics (AMEX: PLX) was reported by HC Wainwright & Co. on October 31, 2023. The analyst firm set a price target for $10.00 expecting PLX to rise to within 12 months (a possible 589.66% upside). 1 analyst firms have reported ratings in the last year.
HC Wainwright及Co.在2023年10月31日报告了Protalix BioTherapeutics（AMEX: PLX）的最新目标价。分析师公司设定了10.00美元的目标价，预计PLX在12个月内上涨至（可能达到589.66%）。在过去一年中，有1家分析师公司报告了评级。
What is the most recent analyst rating for Protalix BioTherapeutics (PLX)?
Protalix BioTherapeutics（PLX）的最新分析师评级是什么？
The latest analyst rating for Protalix BioTherapeutics (AMEX: PLX) was provided by HC Wainwright & Co., and Protalix BioTherapeutics maintained their buy rating.
HC Wainwright及Co.提供了Protalix BioTherapeutics（AMEX: PLX）的最新分析师评级，而Protalix BioT尼疆维克有效地保持了他们的买入评级。
When is the next analyst rating going to be posted or updated for Protalix BioTherapeutics (PLX)?
Protalix BioTherapeutics（PLX）的下一个分析师评级将在何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protalix BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protalix BioTherapeutics was filed on October 31, 2023 so you should expect the next rating to be made available sometime around October 31, 2024.
分析师经过广泛研究后得出股票评级，这包括查阅公开的基本报表，与Protalix BioTherapeutics的高管和客户交谈，并聆听业绩会议的内容。大多数分析师每三个月进行一次此类工作，因此您应该每年为每家公司的每家公司获得4个评级。Protalix BioTherapeutics的最后一次评级是于2023年10月31日提交的，因此您应该期望下一个评级将在大约2024年10月31日左右发布。
Is the Analyst Rating Protalix BioTherapeutics (PLX) correct?
Protalix BioTherapeutics（PLX）的分析师评级是否准确？
While ratings are subjective and will change, the latest Protalix BioTherapeutics (PLX) rating was a maintained with a price target of $7.00 to $10.00. The current price Protalix BioTherapeutics (PLX) is trading at is $1.45, which is out of the analyst's predicted range.
尽管评级是主观的且会改变，但最新的Protalix BioTherapeutics（PLX）评级是保持在7.00到10.00美元的目标价范围内。目前Protalix BioTherapeutics（PLX）的当前价格为1.45美元，已经超出了分析师预测的区间。
